Home>Topics>>Johnson & Johnson/Gilead Deal Could Yield More Combinations in HIV
Johnson & Johnson/Gilead Deal Could Yield More Combinations in HIV
Healthcare Sector and Stocks Analysis from Seeking Alpha
Thu, 30 Jun 2011
EP Vantage submits: Johnson and Johnson 's ( JNJ ) new licensing agreement with Gilead Sciences ( GILD ) for its protease inhibitor Prezista to develop a new combination drug using booster drug cobicistat says a lot about the clever life-cycle management strategy J&J has come up with for the drug. ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.